Browsing by Author "Briasoulis, E."
Now showing items 1-7 of 7
-
Alterations of microRNAs in solid cancers and their prognostic value
Chira, P.; Vareli, K.; Sainis, I.; Papandreou, C.; Briasoulis, E. (2010)MicroRNAs (miRNAs) are evolutionarily conserved, naturally abundant, small, regulatory non-coding RNAs that inhibit gene expression at the post-transcriptional level in a sequence-specific manner. Each miRNA represses the ... -
Association of Syndecan-1 with Angiogenesis-related Markers, Extracellular Matrix Components, and Clinicopathological Features in Colorectal Carcinoma
Mitselou, A.; Skoufi, U.; Tsimogiannis, K. E.; Briasoulis, E.; Vougiouklakis, T.; Arvanitis, D.; Ioachim, E. (2012)Syndecan-1 is a transmembrane heparansulfate proteoglycan, which regulates cell proliferation, migration, angiogenesis, cell-to-cell and cell-to-extracellular matrix adhesion and may influence malignant cell behavior. We ... -
Cytokine effects on cell survival and death of A549 lung carcinoma cells
Kastamoulas, M.; Chondrogiannis, G.; Kanavaros, P.; Vartholomatos, G.; Bai, M.; Briasoulis, E.; Arvanitis, D.; Galani, V. (2013)Purpose: IL-13, TNF-alpha and IL-1 beta have various effects on lung cancer growth and death, but the signaling pathways mediating these effects have not been extensively analyzed. Therefore, the effects of IL-13, TNF-alpha ... -
Docetaxel and Intermittent Erlotinib in Patients with Metastatic Non-small Cell Lung Cancer; A Phase II Study From The Hellenic Cooperative Oncology Group
Karavasilis, V.; Kosmidis, P.; Syrigos, K. N.; Mavropoulou, P.; Dimopoulos, M. A.; Kotoula, V.; Pectasides, D.; Boukovinas, I.; Klouvas, G.; Kalogera-Fountzila, A.; Papandreou, C. N.; Fountzilas, G.; Briasoulis, E. (2014)Aim: To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating chemotherapy-naive patients with advanced Non-Small Cell Lung Cancer (NSCLC). Patients and Methods: Patients were ... -
Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression
Ioachim, E.; Charchanti, A.; Briasoulis, E.; Karavasilis, V.; Tsanou, H.; Arvanitis, D. L.; Agnantis, N. J.; Pavlidis, N. (2002)The immunohistochemical expression of the extracellular matrix (ECM) components tenascin (TN), fibronectin (FN), collagen type IV (Coll) and laminin (LN), and their possible relationships were studied in a series of 134 ... -
Revisiting bleomycin from pathophysiology to safe clinical use
Froudarakis, M.; Hatzimichael, E.; Kyriazopoulou, L.; Lagos, K.; Pappas, P.; Tzakos, A. G.; Karavasilis, V.; Daliani, D.; Papandreou, C.; Briasoulis, E. (2013)Bleomycin is a key component of curative chemotherapy regimens employed in the treatment of curable cancers, such as Hodgkin lymphoma (HL) and testicular germ-cell tumours (GCT), yet its use may cause bleomycin-induced ... -
Thrombospondin-1 expression in breast cancer: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components
Ioachim, E.; Damala, K.; Tsanou, E.; Briasoulis, E.; Papadiotis, E.; Mitselou, A.; Charhanti, A.; Doukas, M.; Lampri, L.; Arvanitis, D. L. (2012)Thrombospondin (TSP-1) is a 450-kd adhesive glycoprotein that was initially discovered in platelets and subsequently in a variety of cell types. Several reports suggest that TSP-1 possesses tumour suppressor function, ...